thiazolid
polypharmacolog
agent
least
three
mechan
action
broad
spectrum
parasit
bacteria
virus
respiratori
virus
inhibit
replic
orthomyxovirida
paramyxovirida
posttransl
level
nitazoxanid
prototyp
thiazolid
origin
develop
antiparasit
agent
later
repurpos
treatment
viral
respiratori
infect
second
gener
thiazolid
follow
nitazoxanid
analogu
also
broadspectrum
antivir
agent
report
effect
circul
metabolit
tizoxanid
deriv
deacetyl
deriv
correspond
deriv
recent
complet
phase
iiiii
clinic
trial
unit
state
canada
australia
new
zealand
total
adult
adolesc
least
month
age
viral
acut
respiratori
ill
sinc
biodisposit
primarili
seen
gastrointestin
tract
efficaci
system
viral
diseas
requir
rel
high
oral
dose
chemic
synthesi
new
deriv
better
system
absorpt
therefor
urgent
need
order
improv
system
absorpt
new
aminoest
prodrug
deriv
prepar
test
anim
pharmacolog
pharmacokinet
toxicolog
rat
show
higher
blood
concentr
compar
absolut
bioavail
increas
good
safeti
profil
anim
safeti
pharmacolog
toxicolog
nitazoxanid
first
thiazolid
discov
rossignol
cavier
broadspectrum
antiparasit
agent
effect
protozoa
nematod
cestod
trematod
regist
throughout
latin
america
egypt
india
bangladesh
treatment
intestin
protozoa
helminth
unit
state
drug
approv
treatment
two
intestin
protozoa
cryptosporidium
parvum
giardia
intestinali
antiprotozo
activ
anaerob
organ
protozoa
bacteria
due
interfer
pyruv
ferredoxin
oxidoreductas
pfor
enzymedepend
electron
transfer
reaction
essenti
anaerob
metabol
helminth
mycobacterium
tuberculosi
disrupt
membran
potenti
homeostasi
intramicroorgan
thiazolid
also
inhibit
protein
disulfid
isomeras
pdi
possess
broad
spectrum
activ
parasit
virus
neospora
caninum
apicomplexan
emerg
protozoa
relat
cryptosporidium
parvum
bind
ncpdi
block
protozoan
replic
respiratori
virus
inhibit
replic
respiratori
virus
belong
class
orthomyxovirida
paramyxovirida
posttransl
level
number
structur
relat
thiazolid
e
g
also
activ
hepat
b
c
virus
low
micromolar
concentr
exampl
rang
respiratori
virus
includ
influenza
strain
exhibit
ic
valu
mgml
rang
flavivirida
includ
hepat
c
mgml
hepat
b
hepadnavirida
mgml
move
vivo
antivir
activ
antivir
activ
tizoxanid
activ
circul
metabolit
confirm
wellcontrol
clinic
trial
carri
patient
treatment
gastroenter
caus
rotaviru
noroviru
uncompl
viral
respiratori
infect
caus
influenza
b
alon
combin
pegylatedinterferon
without
ribavirin
treatment
chronic
partial
absorb
gastrointestin
tract
given
human
volunt
show
oral
dose
excret
via
urin
excret
faec
perfect
biodisposit
profil
drug
intend
treat
intestin
pathogen
much
less
desir
system
antivir
agent
upon
oral
absorpt
immedi
metabol
deacetyl
deriv
subsequ
metabol
liver
tizoxanideglucuronid
rapidli
elimin
via
urin
ideal
treatment
viral
system
infect
oppos
parasit
virus
infect
intestin
tract
call
compound
better
oral
biodisposit
metabol
ideal
liber
blood
stream
activ
circul
metabolit
inact
glucuronid
consider
amount
safeti
efficaci
data
accumul
deriv
unit
state
abroad
last
year
summari
thiazolid
typifi
nitazoxanid
scheme
activ
circul
metabolit
tizoxanid
shown
among
larg
number
analogu
synthesis
chloro
analogu
similarli
circul
metabolit
also
good
broadspectrum
antivir
activ
although
oacet
satisfactorili
taken
passiv
absorpt
behav
effect
ester
prodrug
oral
bioavail
absenc
food
typic
therefor
set
design
robust
prodrug
form
improv
oral
absorpt
solubl
properti
parent
drug
impress
aminoacid
base
prodrug
ester
antivir
agent
valacyclovir
scheme
improv
oral
bioavail
acyclovir
greatli
improv
aqueou
solubl
valacyclovir
enter
cell
via
hpept
transport
initi
therefor
prepar
direct
analogu
tizoxanid
name
valyl
ester
scheme
deriv
readili
prepar
hcl
salt
shown
cf
scheme
unfortun
stabil
prove
inadequ
week
storag
room
temperatur
hydrolysi
signific
releas
parent
drug
nmr
evid
consid
stabl
ester
result
increas
steric
bulk
aminoacid
side
chain
therefor
turn
next
correspond
deriv
ltertleucin
scheme
reaction
boctleoh
use
edc
catalys
dmap
thf
afford
protect
ester
satisfactori
yield
chromatographi
later
found
dmf
superior
solvent
especi
perform
well
scaleup
deliv
yield
deprotect
conveni
achiev
treatment
hcldioxan
hcl
salt
product
could
crystallis
directli
reaction
medium
obtain
excel
yield
importantli
show
appreci
hydrolysi
stand
c
three
month
seen
nmr
analysi
hplc
aqueou
solubl
approxim
mgml
paramount
import
assay
chiral
puriti
comparison
valacyclovir
typic
obtain
acyclovir
ee
boctleoh
senantiom
use
dmf
solvent
obtain
puriti
hplc
ee
start
correspond
deriv
dtertleucin
chiral
hplc
analysi
e
e
determin
note
chlorothiazolid
anoth
import
compound
correspond
prodrug
similarli
made
scheme
intermedi
isol
crystallin
solid
deprotect
proceed
smoothli
afford
hcl
salt
white
solid
excel
yield
product
show
similar
stabil
behaviour
hydrolysi
month
c
aqueou
solubl
greater
approxim
mgml
stabil
valacyclovir
extens
studi
order
probe
issu
stabil
chiral
puriti
product
also
prepar
isoleucin
alloisoleucin
deriv
scheme
see
support
inform
scrambl
nmr
peak
could
seen
either
product
nmr
detect
level
epimeris
would
gener
diastereoisomer
mixtur
possibl
differ
extent
two
product
might
intuit
expect
stabil
compound
nmr
hydrolysi
month
c
greater
less
compound
given
oral
remain
gut
order
assess
absolut
bioavail
new
aminoacid
ester
deriv
comparison
carri
four
parallel
studi
one
includ
six
spraguedawley
rat
weigh
g
divid
two
group
three
anim
four
studi
group
three
rat
treat
singl
oral
dose
four
compound
second
group
three
rat
receiv
singl
intraven
inject
four
test
compound
four
compound
oral
dose
calcul
mgkg
intraven
inject
mgkg
viz
time
less
serial
blood
sampl
obtain
anim
min
h
postdos
note
tizoxanid
glucuronid
scheme
major
vivo
metabolit
signific
concentr
note
min
upon
oral
administr
either
also
time
maximum
plasma
concentr
comparison
auc
calcul
pharmacokinet
paramet
obtain
oral
intraven
administr
show
absolut
bioavail
versu
correct
dose
given
mgkg
versu
correct
dose
mgkg
interestingli
chloroderiv
much
less
bioavail
comparison
auc
show
essenti
oral
absorpt
scheme
synthesi
ltertleucyl
thiazolid
prodrug
reagent
boctleoh
edc
dmap
thf
dmf
ii
hcldioxan
c
abbrevi
tle
ltertleucin
acid
scheme
isoleucyl
alloisoleucyl
prodrug
aminoest
deriv
show
absolut
bioavail
versu
versu
correct
valu
intraven
dose
demonstr
better
pharmacokinet
profil
aminoacid
ester
deriv
correspond
oacetyl
compound
glucuronid
metabolit
quickli
observ
administr
rm
main
vivo
metabolit
bioavail
four
compound
summaris
tabl
detail
post
oral
intraven
blood
level
see
support
inform
therefor
decid
proceed
complet
preclin
develop
rm
order
perform
phase
human
trial
full
pharmacokinet
data
four
compound
rm
rm
rm
given
support
inform
addit
new
deriv
activ
vitro
antivir
right
equival
parent
thiazolid
full
detail
publish
separ
two
safeti
pharmacolog
studi
evalu
effect
central
nervou
system
respiratori
function
respect
rat
singl
oral
dose
mgkg
administ
three
group
rat
male
femal
oral
gavag
one
group
untreat
anim
kept
control
abnorm
sign
record
h
treatment
mgkg
dose
mgkg
dose
level
decreas
activ
decreas
abdomin
tone
labor
breath
tremor
pain
respons
observ
anim
group
suggest
dose
level
produc
cn
toxic
without
mortal
anim
treat
high
dose
second
studi
singl
oral
dose
mgkg
given
oral
gavag
three
group
six
consciou
rat
male
femal
studi
effect
test
drug
respiratori
function
one
group
untreat
anim
kept
control
minor
chang
respiratori
rate
express
breath
per
minut
tidal
volum
observ
low
mgkg
mgkg
oral
dose
without
affect
minut
volum
dose
pronounc
effect
three
paramet
record
describ
observ
mgkg
dose
suggest
level
effect
respiratori
function
rat
howev
mortal
record
three
dose
level
test
dose
schedul
summaris
tabl
two
subacut
toxic
studi
rm
carri
spraguedawley
rat
beagl
dog
first
studi
involv
dosag
rat
three
separ
dose
level
mgkg
rm
day
consecut
day
evalu
system
exposur
drug
termin
advers
effect
note
rat
bright
yellow
urin
commonli
observ
link
formul
rm
yellow
suspens
weight
loss
observ
especi
male
group
within
accept
limit
conclud
observ
advers
effect
level
noael
achiev
dose
mgkg
full
toxicolog
detail
given
support
inform
dose
group
number
summaris
tabl
second
studi
evalu
system
exposur
administ
oral
via
gelatin
capsul
three
separ
dose
level
mgkg
day
consecut
day
beagl
dog
earli
death
dog
studi
period
bright
yellow
urin
commonli
observ
case
emesi
yellow
particul
materi
case
howev
emesi
observ
control
anim
anim
studi
exposur
appar
base
overal
studi
data
high
dose
level
mgkgday
rm
administ
singl
gelatin
capsul
consecut
day
beagl
dog
consid
observ
advers
effect
level
noael
full
detail
given
support
inform
dose
group
number
summaris
tabl
nitazoxanid
origin
design
broadspectrum
antiparasit
drug
treatment
intestin
protozoan
helminth
infect
drug
market
around
world
year
recent
repurpos
broadspectrum
antivir
agent
treatment
viral
acut
respiratori
infect
phase
iii
clinic
trial
carri
adult
adolesc
uncompl
influenza
b
show
drug
reduc
durat
influenza
ill
compar
placebo
p
valu
addit
studi
show
nitazoxanid
compar
placebo
effect
treatment
common
cold
caus
rhinoviru
coronaviru
studi
patient
viral
respiratori
infect
risk
develop
complic
children
adult
children
sever
acut
respiratori
infect
sari
current
underway
import
identifi
new
deriv
better
system
absorpt
shown
second
prodrug
tizoxanid
solubl
better
absorb
laboratori
anim
undergo
phase
clinic
trial
may
provid
oral
dose
effect
lower
dosag
importantli
inject
form
tizoxanid
nitazoxanid
unabl
organ
extract
wash
final
satd
aq
nacl
dri
anhydr
na
prior
rotari
evapor
c
analyt
thinlay
chromatographi
perform
use
merck
kieselgel
f
silica
plate
prepar
column
chromatographi
perform
merck
silica
gel
unless
otherwis
state
h
c
nmr
spectra
record
cdcl
solut
use
either
bruker
mhz
mhz
c
instrument
tetramethylsilan
intern
standard
lowand
highresolut
mass
spectra
obtain
direct
inject
sampl
solut
micromass
lct
mass
spectromet
oper
electrospray
mode
ion
indic
ci
mass
spectra
nh
obtain
fison
instrument
trio
analyt
hplc
perform
use
ascentia
express
column
elut
gradient
mecn
vv
cf
co
h
monitor
nm
chiral
hplc
perform
use
chiralpak
adh
column
elut
nc
h
pr
oh
microanalyt
data
obtain
use
elementar
vario
micro
cube
instrument
mixtur
boctleoh
g
mmol
tizoxanid
g
mmol
stir
c
anhydr
thf
ml
nethyln
dimethylamino
propyl
carbodiimid
hcl
edc
g
mmol
ad
one
portion
follow
immedi
dmap
g
mmol
h
mixtur
filter
celit
precipit
wash
thf
dilut
ethyl
acet
ml
combin
filtrat
wash
wash
aq
citric
acid
satur
aq
nahco
water
brine
dri
anhydr
na
evapor
afford
yellow
foam
chromatograph
silica
gel
appli
ch
cl
elut
ethyl
acet
hexan
appropri
fraction
combin
evapor
afford
titl
compound
later
found
use
dmf
solvent
eq
edc
dmap
reagent
could
fulli
dissolv
convers
obtain
h
c
final
isol
yield
similar
highest
ee
observ
dmf
use
coupl
step
follow
deprotect
obtain
hplc
area
puriti
chiral
puriti
correspond
r
enantiom
viz
deriv
dtertleucin
similarli
made
materi
hplc
puriti
chiral
puriti
synthesi
character
compound
boc
precursor
togeth
detail
pharmacokinet
toxicolog
method
employ
see
support
inform
